Market Research Report
Soft Tissue Sarcoma (STS) - Epidemiology Forecast - 2030
|Published by||DelveInsight Business Research LLP||Product code||534995|
|Published||Content info||122 Pages
Delivery time: 1-2 business days
|Soft Tissue Sarcoma (STS) - Epidemiology Forecast - 2030|
|Published: February 1, 2020||Content info: 122 Pages||
DelveInsight's 'Soft Tissue Sarcoma (STS) - Epidemiology Forecast-2030' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology trends of STS in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
According to the World Health Organization (WHO), there are more than 50 histologic subtypes of STSs. The signs and symptoms of STSs vary greatly from patients to patients based on the type of STS. However, it is not associated with any noticeable symptoms early in the course of the disease but the affected individuals may notice slow-growing, painless mass in the affected area.
According to DelveInsight's, STS has various subtypes. It was observed that in the United States and European countries, liposarcoma and leiomyosarcoma were the most incident subtypes of STS, which contributed to the majority of the cases. Whereas in Japan, subtypes, fibroblastic sarcomas and liposarcoma were more common.
Study Period: 2017-2030.
Soft-tissue sarcoma (STS) are rare neoplasms that can develop in supporting or connective tissue, such as the muscle, nerves, tendons, blood vessels and fatty and fibrous tissues. They commonly affect the arms, legs, and trunk. They also appear in the stomach and intestines (GIST) as well as behind the abdomen (retroperitoneal sarcomas) and the female reproductive system (gynecological sarcomas). STSs may be classified according to the involved cell-type, the specific nature of the malignancy, and the disease's clinical course.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Incident Cases of Soft Tissue Sarcoma (STS) in the 7MM, Type-specific Incidence Cases of Soft Tissue Sarcoma in the 7MM, Total Incident Cases of Gastrointestinal Stromal Tumor (GIST) in the United States, Total Incident Cases of STS including GIST in the United States and Incidence of STS by Extremities (%) in the 7MM scenario of STS in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017-2030.
According to DelveInsight's, the total incident population of Soft Tissue Sarcoma (STS) in seven major markets was 40,155 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017-2030).
Among all the seven major markets, the United States accounts for the highest number of cases of STS. In 2017, there were 12,390 incident cases of STS-which did not include GIST cases-in the United States. The total incident cases of GIST which were observed in the United States in 2017 accounted for 5,090. This lead to the total incident population of STS to 17,480 in 2017.
In European countries, GIST cases are not included in the STS population. Germany had the highest incident population of STS with 4,781 cases, followed by Italy which had an incident population of 4,082 in 2017. On the other hand, Spain had the lowest incident population of 2,445 in 2017.